Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,308
archived clinical trials in
Hepatitis

Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Status: Enrolling
Updated:  6/14/2012
Mochida Investigative Site
mi
from
Seattle, WA
Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With Non Alcoholic Steatohepatitis (NASH)
A Phase II Double-Blind, Placebo-Controlled Study of Two Doses of EPA-E in Patients With NASH
Status: Enrolling
Updated: 6/14/2012
Mochida Investigative Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Japanese Bridging Study Conducted in the United States
A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects
Status: Enrolling
Updated:  6/18/2012
Local Institution
mi
from
Inglewood, CA
Japanese Bridging Study Conducted in the United States
A Randomized, Placebo-Controlled, Single and Multiple Ascending-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-791325 in Healthy Japanese Subjects
Status: Enrolling
Updated: 6/18/2012
Local Institution
mi
from
Inglewood, CA
Click here to add this to my saved trials
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Status: Enrolling
Updated:  7/18/2012
Hartford Dispensary
mi
from
Hartford, CT
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Computer-based Cognitive Behavioral Therapy for Risky Behaviors in Opioid Dependent Patients
Status: Enrolling
Updated: 7/18/2012
Hartford Dispensary
mi
from
Hartford, CT
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Santa Clara, CA
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Decatur, GA
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Decatur, GA
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Park Ridge, IL
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Boston, MA
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Rochester, MN
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Rochester, MN
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Newark, NJ
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Newark, NJ
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
New York, NY
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Cleveland, OH
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated:  7/23/2012
Clinical Research Facility
mi
from
Dallas, TX
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Evaluation of HepaGam B® in Combination With Antiviral Treatment in Hepatitis B Liver Transplant Patients
Status: Enrolling
Updated: 7/23/2012
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM5)
A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials
Status: Enrolling
Updated:  8/15/2012
Clinical Research Facility
mi
from
San Antonio, TX
A Study of Vaniprevir (MK-7009) in Patients With Chronic Hepatitis C Infection After Participation in Other Vaniprevir Studies (MK-7009-028 AM5)
A Phase II Open Label Study of MK-7009 Administered Concomitantly With Pegylated Interferon Alfa-2a and Ribavirin to Patients With Chronic Hepatitis C Infection After Participation in Other MK-7009 Clinical Trials
Status: Enrolling
Updated: 8/15/2012
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
UCLA Medical Center-The Pfleger Liver Institute
mi
from
Los Angeles, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
UCLA Medical Center-The Pfleger Liver Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
UC San Diego
mi
from
San Diego, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
UC San Diego
mi
from
San Diego, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of California, San Francisco
mi
from
San Francisco, CA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of California, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of Colorado Hospital
mi
from
Aurora, CO
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of Colorado Hospital
mi
from
Aurora, CO
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
University of Miami
mi
from
Miami, FL
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
University of Miami
mi
from
Miami, FL
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Mount Sinai Medical Center
mi
from
Miami Beach, FL
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Mount Sinai Medical Center
mi
from
Miami Beach, FL
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Beth Israel Deaconess Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Lahey Clinic Medical Center
mi
from
Burlington, MA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Lahey Clinic Medical Center
mi
from
Burlington, MA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Henry Ford Hospital
mi
from
Detroit, MI
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Henry Ford Hospital
mi
from
Detroit, MI
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
St. Louis University Hospital
mi
from
St. Louis, MO
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
St. Louis University Hospital
mi
from
St. Louis, MO
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Columbia University
mi
from
New York, NY
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Columbia University
mi
from
New York, NY
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Thomas Jefferson University Hospital
mi
from
Philadelphia, PA
Click here to add this to my saved trials
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated:  8/16/2012
Baylor Health Care System
mi
from
Dallas, TX
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
An Open-Label Study to Explore the Clinical Efficacy of GS 7977 With Ribavirin Administered Pre-Transplant in Preventing Hepatitis C Virus (HCV) Recurrence Post-Transplant
Status: Enrolling
Updated: 8/16/2012
Baylor Health Care System
mi
from
Dallas, TX
Click here to add this to my saved trials
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
An Investigator-initiated Pilot Study Using Statins to Improve the Anti-HCV Response to Peginterferon Alfa 2-b and Ribavirin in Previous Non-responders
Status: Enrolling
Updated:  8/20/2012
Veterans Administration Medical Center (VAMC)
mi
from
Oklahoma City, OK
HCV Treatment With Fluvastatin, Simvastatin to Improve Interferon Sensitivity
An Investigator-initiated Pilot Study Using Statins to Improve the Anti-HCV Response to Peginterferon Alfa 2-b and Ribavirin in Previous Non-responders
Status: Enrolling
Updated: 8/20/2012
Veterans Administration Medical Center (VAMC)
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Mobile, AL
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Mobile, AL
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Long Beach, CA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Long Beach, CA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
San Diego, CA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
San Rafael, CA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
San Rafael, CA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Brandenton, FL
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Brandenton, FL
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Miami, FL
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Downers Grove, IL
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Downers Grove, IL
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
New Orleans, LA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Shreveport, LA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Shreveport, LA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Baltimore, MD
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Baltimore, MD
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Boston, MA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Burlington, MA
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Burlington, MA
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Detroit, MI
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Detroit, MI
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Plymouth, MN
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Plymouth, MN
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Kansas City, MO
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Kansas City, MO
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Springfield, MO
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Springfield, MO
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
Manhasset, NY
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
Manhasset, NY
Click here to add this to my saved trials
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated:  8/27/2012
Clinical Research Facility
mi
from
New York, NY
Three-year Follow-up of Subjects After Administration of Boceprevir or Narlaprevir for the Treatment of Chronic Hepatitis C (P05063AM1)
Long-Term Follow-Up of Subjects in a Phase 1, 2, or 3 Clinical Trial in Which Boceprevir or Narlaprevir Was Administered for the Treatment of Chronic Hepatitis C
Status: Enrolling
Updated: 8/27/2012
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials